HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies ; volume:179 ; number:3 ; day:8 ; month:11 ; year:2019 ; pages:543-555 ; date:2.2020
Breast cancer research and treatment ; 179, Heft 3 (8.11.2019), 543-555, 2.2020
- Creator
-
Tracey, Natasha
Creedon, Helen
Kemp, Alain J.
Culley, Jayne
Muir, Morwenna
Klinowska, Teresa
Brunton, Valerie G.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-019-05489-1
- URN
-
urn:nbn:de:101:1-2020050322562701514006
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tracey, Natasha
- Creedon, Helen
- Kemp, Alain J.
- Culley, Jayne
- Muir, Morwenna
- Klinowska, Teresa
- Brunton, Valerie G.
- SpringerLink (Online service)
Other Objects (12)
HER2-targeted therapies in cancer: a systematic review
Targeted therapies for ER+/HER2- metastatic breast cancer
Recombinant immunotoxins development for HER2-based targeted cancer therapies
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Targeted therapies for cancer
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
HER2-targeted therapies in cancer: a systematic review
Targeted therapies for ER+/HER2- metastatic breast cancer
Recombinant immunotoxins development for HER2-based targeted cancer therapies
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Targeted therapies for cancer
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
HER2-targeted therapies in cancer: a systematic review
Targeted therapies for ER+/HER2- metastatic breast cancer
Recombinant immunotoxins development for HER2-based targeted cancer therapies
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Targeted therapies for cancer
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology